ProQR Therapeutics NV has received authorization from the Central Committee on Research Involving Human Subjects (CCMO) for its Clinical Trial Application $(CTA)$ to begin a Phase 1 study of AX-0810 in healthy volunteers. This approval follows review under the European Medicines Agency's centralized process. AX-0810 is ProQR's lead investigational editing oligonucleotide targeting NTCP, being developed for the treatment of cholestatic diseases such as primary sclerosing cholangitis and biliary atresia. The Phase 1 trial, to be conducted in the Netherlands, will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AX-0810.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-100627), on October 20, 2025, and is solely responsible for the information contained therein.